Radiopharm Theranostics Limited - RADX Operating profit EBITDA
Radiopharm Theranostics (RADX) aims for dominance in nuclear medicine by expanding its portfolio of alpha and beta therapies. Tracking EBITDA, with chart data sourced from GURU.Markets, confirms stable flows, while the 0.00 level reflects the current profit magnitude. Supply security is guaranteed by strict control over isotope decay timelines. The development of innovative theranostics allows for the integration of diagnostics with the targeted destruction of tumors.
Radiopharm Theranostics (RADX) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Radiopharm Theranostics|RADX - Long-Term Debt to Capital|Short-Term Debt to Capital radiopharmtheranostics.com|RADX - Company Aggregate Debts|Debt to Book Value Ratio Radiopharm Theranostics|RADX - Company Long-Term Debts|Short-Term Debt Volume Radiopharm Theranostics|Immediate Liquidity radiopharmtheranostics.com
- earnings and market ratios statistics:
RADX - Company Net Income|Forward Earnings Radiopharm Theranostics|RADX - P/E Multiple|Future Price to Earnings Multiple Radiopharm Theranostics Ltd|RADX - PEG Multiple|EV/EBITDA Multiple Radiopharm Theranostics|RADX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Radiopharm Theranostics|RADX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months radiopharmtheranostics.com|RADX - Net earnings per share growth this year|Expected earnings per share trend next year Radiopharm Theranostics
Summary company analytics:Radiopharm Theranostics Ltd - RADX
For Radiopharm Theranostics (RADX), which is protected by patents for isotopes in nuclear medicine, monitoring operating profit in cash terms reflects the actual efficiency of drug commercialization. This indicator measures cash flow from core operations before depreciation, allowing investors to filter out speculative noise and assess the business's resilience to market shocks, thereby preventing overpayment for the asset during periods of high volatility.
Who Radiopharm Theranostics competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS (erasca.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|Aura Bio - Operating profit EBITDA|CADL (Candel Therapeutics) - Operating profit before amortization|ARAY: Operating profit EBITDA|SLS - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Actuate Therapeutics|Profit before interest, taxes and amortization Citius Oncology Inc. CTOR|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|TARA: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA FATE (Fate Therapeutics, Inc.)|Income before deduction of interest, taxes and amortization WHWK|TScan - Operating profit EBITDA|CSBR - Operating profit EBITDA|xbiotech.com (XBIT) - Profit before payment of interest, taxes and amortization|CEL-SCI - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization OS Therapies Incorporated|Operating profit before deduction of amortization Artiva (ARTV)|Operating profit before deduction of amortization ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Income before deduction of interest, taxes and amortization|Tempest Tx - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization XLO (Xilio Therapeutics Inc)|Enochian BioSciences - Operating profit EBITDA|Income before deduction of interest, taxes and amortization MURA (Mural Oncology plc)|KAPA: Operating profit EBITDA|Profit before interest, taxes and amortization OnKure Therapeutics (OKUR)|Profit before payment of interest, taxes and amortization CytoMed Therapeutics Ltd|CRIS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA APLM|Operating profit EBITDA tharimmune.com (THAR)|Profit before payment of interest, taxes and amortization Advanced Biomed ADVB|GNPX: Operating profit before amortization|CLDI - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization sunshinebiopharma.com|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|SLRX - Operating income before deduction of amortization|Operating profit before deduction of amortization PPBT|AONC (AON) - Company profit before taxes, interest and amortization|Operating profit EBITDA BGNE|Operating income before deduction of amortization Checkpoint Therapeutics Inc|Operating profit EBITDA ELEV (Elevation Oncology)|ICAD - Operating profit before deduction of amortization|IKNA - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Notable Labs Ltd NTBL|viracta.com (VIRX) - Profit before payment of interest, taxes and amortization|MorphoSys Corporation - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit EBITDA ascentage.com
